Literature DB >> 7437237

Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.

A J Marshall, M A Kettle, D W Barritt.   

Abstract

1 Indoramin, an alpha-adrenoreceptor blocking agent has been given as a third agent to patients with severe hypertension treated with adequate doses of a beta-adrenoceptor blocking drug and a thiazide diuretic. 2 A further fall in blood pressure followed the addition of indoramin. With 75 mg twice daily this was on average a fall of 12% of mean arterial pressure in the supine position, 16% standing an 17% after exercise. 3 The rise in blood pressure caused by isometric exercise was not altered by indoramin. 4 Indoramin slowed the heart rate. On 75 mg twice daily the reduction was 14% at rest and 19% after exercise. 5 Side effects of indoramin were sedation, sleep disturbance and vivid dreams.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437237      PMCID: PMC1430069          DOI: 10.1111/j.1365-2125.1980.tb01747.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Beta blockade in essential hypertension: an analysis of response to oxprenolol.

Authors:  D W Barritt; A J Marshall
Journal:  Br Heart J       Date:  1977-08

2.  Clinical evaluation of indoramin, a new antihypertensive agent.

Authors:  P J Lewis; C F George; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1973-12       Impact factor: 2.953

3.  Pharmacologic studies of indoramin in man.

Authors:  R B Royds; D J Coltart; J D Lockhart
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

4.  Some clinical pharmacological studies with indoramin, with observations on its therapeutic usefulness.

Authors:  C de White; R B Royds; P Turner
Journal:  Postgrad Med J       Date:  1974-12       Impact factor: 2.401

5.  Atenolol and bendrofluazide in hypertension.

Authors:  J C Petrie; D B Galloway; J Webster; W T Simpson; J A Lewis
Journal:  Br Med J       Date:  1975-10-18

6.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

7.  The alpha-adrenoceptor blocking effect of indoramin on human isolated smooth muscle.

Authors:  D H Variava; P Turner
Journal:  J Pharm Pharmacol       Date:  1973-08       Impact factor: 3.765

8.  The evaluation of the alpha-adrenoceptor blocking action of indoramin, phentolamine and thymoxamine on the rat and guinea-pig isolated mesenteric vasculature and aortic spiral preparations.

Authors:  M G Collis; B J Alps
Journal:  J Pharm Pharmacol       Date:  1973-08       Impact factor: 3.765

9.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

10.  Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.

Authors:  A J Marshall; D W Barritt; J Pocock; S T Heaton
Journal:  Lancet       Date:  1977-02-05       Impact factor: 79.321

View more
  2 in total

Review 1.  Drugs interacting with alpha adrenoceptors.

Authors:  P A van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

Review 2.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.